A Reversal for Spero Therapeutics, Inc. (SPRO) Is Not Near. The Stock Reaches All-Time Low Today

December 7, 2017 - By Henry Gaston

The stock of Spero Therapeutics, Inc. (NASDAQ:SPRO) reached all time low today, Dec, 7 and still has $9.49 target or 9.00 % below today’s $10.43 share price. This indicates more downside for the $149.80 million company. This technical setup was reported by Barchart.com. If the $9.49 PT is reached, the company will be worth $13.48M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 8.87% or $1.015 during the last trading session, reaching $10.425. About 66,286 shares traded. Spero Therapeutics, Inc. (NASDAQ:SPRO) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Spero Therapeutics, Inc. (NASDAQ:SPRO) Ratings Coverage

Among 4 analysts covering Spero Therapeutics (NASDAQ:SPRO), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Spero Therapeutics had 4 analyst reports since November 27, 2017 according to SRatingsIntel. Oppenheimer initiated it with “Buy” rating and $30.0 target in Monday, November 27 report. The stock of Spero Therapeutics, Inc. (NASDAQ:SPRO) has “Buy” rating given on Monday, November 27 by Cowen & Co. The rating was initiated by Bank of America with “Hold” on Monday, November 27.

More notable recent Spero Therapeutics, Inc. (NASDAQ:SPRO) news were published by: Pehub.com which released: “VC-backed Spero Therapeutics files for IPO” on October 09, 2017, also Globenewswire.com with their article: “Spero Therapeutics Launches Initial Public Offering” published on October 23, 2017, Globenewswire.com published: “Spero Therapeutics, Inc. (Nasdaq: SPRO) to Ring The Nasdaq Stock Market …” on November 20, 2017. More interesting news about Spero Therapeutics, Inc. (NASDAQ:SPRO) were released by: Globenewswire.com and their article: “Spero Therapeutics Files Registration Statement for Proposed Initial Public …” published on October 06, 2017 as well as Globenewswire.com‘s news article titled: “Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994” with publication date: October 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.